IN THE CLAIMS

Please amend claims 1-8 and 30-32 as follows:

B1

1. A pharmaceutical formulation for intranasal administration comprising morphine sulfate at a pH from about 3.0 to about 7.0.

2. A pharmaceutical formulation according to Claim 1 comprising a therapeutically effective amount of morphine or sulfate eliciting an analgesic or anesthetic response in a mammal.

3. A pharmaceutical formulation according to Claim 1, further comprising morphine sulfate in combination with a nasal delivery system.

4. A pharmaceutical formulation according to Claim 3, wherein morphine sulfate is dispersed in an aqueous or non-aqueous formulation.

5. A pharmaceutical formulation according to Claim 4, wherein morphine sulfate is at a concentration below about 50% w/w.

6. A pharmaceutical formulation according to Claim 4, wherein morphine sulfate is at a concentration below about 10% w/w.

7. A pharmaceutical formulation according to Claim 4, wherein morphine sulfate is dispersed in suspensions, solutions, powders, gels, ointments and creams.

8. A pharmaceutical formulation according to Claim 3, wherein the nasal delivery system comprises a buffer to maintain the pH of the morphine sulfate, a thickening agent, a humectant, an absorption enhancer and combinations thereof.

B2

30. A pharmaceutical formulation, according to Claim 1, for intranasal administration comprising morphine sulfate at a pH of 3.5.

31. A pharmaceutical formulation according, to Claim 1, for intranasal administration comprising morphine sulfate at a pH of 4.0.

32. A pharmaceutical formulation according to Claim 1, for intranasal administration comprising morphine sulfate at a pH from about 5.0 to about 6.0.